These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 25355310

  • 1. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
    Cady RK, McAllister PJ, Spierings EL, Messina J, Carothers J, Djupesland PG, Mahmoud RA.
    Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
    [Abstract] [Full Text] [Related]

  • 2. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J.
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [Abstract] [Full Text] [Related]

  • 3. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.
    Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA, Siffert J.
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
    McGinley JS, Buse DC, Shulman KJ, Wirth RJ, Hugentobler E, Lipton RB.
    Headache; 2019 Jul; 59(7):1002-1013. PubMed ID: 31062349
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
    Schulman EA.
    Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
    Obaidi M, Offman E, Messina J, Carothers J, Djupesland PG, Mahmoud RA.
    Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sumatriptan (oral route of administration) for acute migraine attacks in adults.
    Derry CJ, Derry S, Moore RA.
    Cochrane Database Syst Rev; 2012 Feb 15; 2012(2):CD008615. PubMed ID: 22336849
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.